Filing Details
- Accession Number:
- 0000902664-24-001230
- Form Type:
- 13G Filing
- Publication Date:
- 2024-02-06 19:00:00
- Filed By:
- Acorn Bioventures, L.p.
- Company:
- Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)
- Filing Date:
- 2024-02-07
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Acorn Bioventures | 0 | 0 | 0 | 0 | 0 | 0 12 TYPE OF REPORTING PERSON PN The information set forth on this cover page reflects information as of the date hereof. As of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 106,823 shares of Common Stock (including (i) 44,657 warrants (the Warrants ), which are exercisable for shares of Common Stock, and (ii) 39,666 shares of Common Stock into which 119,000 shares of Series B Convertible Preferred Stock (the Series B Preferred Stock ) are convertible at the option of the holder), representing 9.68% |
| Acorn Capital Advisors GP | 0 | 0 | 0 | 0 | 0 | 0 12 TYPE OF REPORTING PERSON OO The information set forth on this cover page reflects information as of the date hereof. As of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 106,823 shares of Common Stock (including (i) 44,657 Warrants, and (ii) 39,666 shares of Common Stock into which 119,000 shares of Series B Convertible Preferred Stock are convertible at the option of the holder), representing 9.68% |
| Anders Hove | 0 | 0 | 0 | 0 | 0 | 0 12 TYPE OF REPORTING PERSON IN The information set forth on this cover page reflects information as of the date hereof. As of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 106,823 shares of Common Stock (including (i) 44,657 Warrants, and (ii) 39,666 shares of Common Stock into which 119,000 shares of Series B Convertible Preferred Stock are convertible at the option of the holder), representing 9.68% |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| SCHEDULE 13G/A | |
| Under the Securities Exchange Act of 1934 | |
| (Amendment No. 2)* | |
| Cyclacel Pharmaceuticals, Inc. | |
| (Name of Issuer) | |
| Common Stock, par value $0.001 per share | |
| (Title of Class of Securities) | |
| 23254L603 | |
| (CUSIP Number) | |
| December 31, 2023 | |
| (Date of Event Which Requires Filing of this Statement) | |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: | |
| ¨ | Rule 13d-1(b) |
| ý | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
| (Page 1 of 8 Pages) | |
______________________________
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 23254L603 | 13G/A | Page 2 of 8 Pages |
| 1 | NAME OF REPORTING PERSON
Acorn Bioventures, L.P. | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ☒ | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0* | ||
| 6 | SHARED VOTING POWER 0 | |||
| 7 | SOLE DISPOSITIVE POWER 0* | |||
| 8 | SHARED DISPOSITIVE POWER 0 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0* | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0* | |||
| 12 | TYPE OF REPORTING PERSON PN | |||
| * | The information set forth on this cover page reflects information as of the date hereof. As of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 106,823 shares of Common Stock (including (i) 44,657 warrants (the “Warrants”), which are exercisable for shares of Common Stock, and (ii) 39,666 shares of Common Stock into which 119,000 shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”) are convertible at the option of the holder), representing 9.68% of the outstanding shares of Common Stock as of such time. |
| CUSIP No. 23254L603 | 13G/A | Page 3 of 8 Pages |
| 1 | NAME OF REPORTING PERSON
Acorn Capital Advisors GP, LLC | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ☒ | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0* | ||
| 6 | SHARED VOTING POWER 0 | |||
| 7 | SOLE DISPOSITIVE POWER 0* | |||
| 8 | SHARED DISPOSITIVE POWER 0 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0* | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0* | |||
| 12 | TYPE OF REPORTING PERSON OO | |||
| * | The information set forth on this cover page reflects information as of the date hereof. As of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 106,823 shares of Common Stock (including (i) 44,657 Warrants, and (ii) 39,666 shares of Common Stock into which 119,000 shares of Series B Convertible Preferred Stock are convertible at the option of the holder), representing 9.68% of the outstanding shares of Common Stock as of such time. |
| CUSIP No. 23254L603 | 13G/A | Page 4 of 8 Pages |
| 1 | NAME OF REPORTING PERSON
Anders Hove | |||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ¨ (b) ☒ | ||
| 3 | SEC USE ONLY | |||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States of America | |||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0* | ||
| 6 | SHARED VOTING POWER 0 | |||
| 7 | SOLE DISPOSITIVE POWER 0* | |||
| 8 | SHARED DISPOSITIVE POWER 0 | |||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0* | |||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0* | |||
| 12 | TYPE OF REPORTING PERSON IN | |||
| * | The information set forth on this cover page reflects information as of the date hereof. As of December 31, 2023, the Reporting Persons may have been deemed to beneficially own 106,823 shares of Common Stock (including (i) 44,657 Warrants, and (ii) 39,666 shares of Common Stock into which 119,000 shares of Series B Convertible Preferred Stock are convertible at the option of the holder), representing 9.68% of the outstanding shares of Common Stock as of such time. |
| CUSIP No. 23254L603 | 13G/A | Page 5 of 8 Pages |
| Item 1(a). | Name of Issuer. |
| Cyclacel Pharmaceuticals, Inc. (the "Issuer") |
| Item 1(b). | Address of Issuer's Principal Executive Offices. |
| 200 Connell Drive, Suite 1500 Berkeley Heights, New Jersey 07922 |
| Item 2(a). | Name of Person Filing. |
| This statement is filed by: |
| (i) | Acorn Bioventures, L.P. (“Acorn”); | |
| (ii) | Acorn Capital Advisors GP, LLC (“Acorn GP”), which is the sole general partner of Acorn; and | |
| (iii) | Anders Hove (“Hove”), who is the manager of Acorn GP. |
| The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." | |
| The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein. |
| Item 2(b). | Address of Principal Business Office. |
| The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170. |
| Item 2(c). | Place of Organization. |
| Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Hove is a citizen of the United States of America. |
| Item 2(d). | Title of Class of Securities. |
| Common stock, $0.001 par value per share (the "Common Stock") |
| Item 2(e). | CUSIP Number. |
| 23254L603 |
| CUSIP No. 23254L603 | 13G/A | Page 6 of 8 Pages |
| Item 3. | If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: |
| (a) | ¨ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); | |
| (b) | ¨ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); | |
| (c) | ¨ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); | |
| (d) | ¨ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); | |
| (e) | ¨ | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); | |
| (f) | ¨ | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | o | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
| |
| (h) | ¨ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
| |
| (i) | ¨ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | ¨ | A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); | |
| (k) | ¨ | Group, in accordance with §240.13d-1(b)(1)(ii)(K). |
| If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please | ||
| specify the type of institution: | ||
| Item 4. | Ownership. |
| The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. | |
| The percentage of class as of December 31, 2023 was calculated based on 1,019,310 shares of Common Stock, as reported in the Issuer’s Prospectus filed pursuant to Rule 424(b)(5) with the Commission on December 26, 2023, after giving effect to the completion of the offering as described therein, and assumes the exercise of the Warrants and conversion of the Series B Preferred Stock. | |
| Acorn GP is the general partner of Acorn and may be deemed to beneficially own the shares of Common Stock beneficially owned by Acorn. | |
| Hove, in his capacity as the manager of Acorn GP, may be deemed to beneficially own the shares beneficially owned by Acorn. |
| CUSIP No. 23254L603 | 13G/A | Page 7 of 8 Pages |
| Item 5. | Ownership of Five Percent or Less of a Class. |
| If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x |
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
| Not applicable. |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
| Not applicable. |
| Item 8. | Identification and Classification of Members of the Group. |
| Not applicable. |
| Item 9. | Notice of Dissolution of Group. |
| Not applicable. |
| Item 10. | Certification. |
| By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
| CUSIP No. 23254L603 | 13G/A | Page 8 of 8 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
| Date: February 7, 2024 | ||
| ACORN BIOVENTURES, L.P. | ||
| By: ACORN CAPITAL ADVISORS GP, LLC, its General Partner | ||
| By: | /s/ Anders Hove | |
| Name: Anders Hove | ||
| Title: Manager | ||
| ACORN CAPITAL ADVISORS GP, LLC | ||
| By: | /s/ Anders Hove | |
| Name: Anders Hove | ||
| Title: Manager | ||
| ANDERS HOVE | ||
| /s/ Anders Hove | ||